HURA · TuHURA Biosciences, Inc./NV · Financials
Market Cap
$133.19M
Shares
63.73M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$0
FY2025
Net Income
-$30.05M
-38.6%
FY2025
Diluted EPS
-$0.63
+47.9%
FY2025
Operating Cash Flow
-$27.63M
-87.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $0 | $0 | $0 | $0 | — | — | — | — | — | — | — | — | — | $0 | — | |
| $22.88M | $20.53M | $13.34M | $9.4M | $15.17M | $11.82M | $3.63M | -$3.66M | -$7.13M | $5M | $3.36M | -$2.56M | $2.34M | $1.55M | $1.05M | |
| $8.15M | $7.58M | $3.87M | $4.14M | $7.51M | $9.76M | $4.51M | -$4.74M | -$4.04M | $3.32M | $2.85M | -$2.17M | $3.95M | $1.15M | $241.8K | |
| — | — | — | $3.23M | — | $2000 | $10K | $16.35K | $24.53K | $16.68K | — | — | — | — | — | |
| $95.41K | $71.27K | $116.71K | $177.38K | — | — | — | — | — | — | — | — | — | — | — | |
| $31.2M | $31.8M | $17.65M | $29.76M | $22.68M | $38.17M | -$9.2M | -$8.4M | -$11.17M | $8.32M | $6.21M | -$4.72M | $6.29M | $2.71M | $1.29M | |
| -$11.52K | — | — | — | — | — | — | — | — | — | — | — | — | -$18.89K | — | |
| — | $625.28K | $4.14M | $18.69K | — | $30K | — | — | — | — | $2091 | -$2091 | $8020 | $7521 | $21.93K | |
| $572.48K | $1.74M | -$4.03M | $447.89K | $21K | -$132K | $72K | -$350.28K | -$36.35K | -$239.07K | -$2.65M | -$376.89K | -$2M | $304.73K | -$40.07K | |
| — | -$30.05M | -$21.68M | $29.3M | — | — | — | — | — | — | — | — | — | — | — | |
| — | $1600 | $3768 | $0 | — | — | — | — | — | — | — | — | — | — | — | |
| -$30.62M | -$30.05M | -$21.68M | -$29.32M | -$22.66M | -$38.3M | -$9.13M | $8.05M | $11.14M | $8.08M | -$8.86M | -$4.35M | -$8.29M | -$2.4M | -$1.33M | |
| -$30.63M | -$30.06M | -$22.65M | -$29.32M | -$25.13M | -$41.5M | -$9.14M | $8.13M | $11.31M | $8.87M | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | -$8.86M | $4.35M | -$8.29M | -$2.42M | -$1.29M | |
| USD/shares | -$0.54 | -$0.63 | -$1.21 | -$2.47 | -$12.90 | -$40.00 | -$21.75 | $79.00 | $13.50 | $18.50 | $20.25 | $2.75 | — | — | — |
| USD/shares | -$0.54 | -$0.63 | -$1.21 | -$2.47 | — | — | — | — | — | — | — | $2.75 | — | — | — |
| shares | — | 47.93M | 18.66M | 11.89M | 1.95M | 1.04M | 417.76K | 102.99K | 834.46K | 481.88K | 437.94K | 1.52M | 1.19M | 529.29K | 341.1K |
| shares | — | 47.93M | 18.66M | 11.89M | — | — | — | — | — | — | — | 1.52M | 1.19M | 529.29K | 341.1K |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 5.24×
EV/EBIT
—
Peer median 10.82×
P/E (TTM)
—
Peer median 8.00×
Peer medians compare against the 307 similar-size Biotechnology companies (of 533 listed).